MUC1 and neoplasm: Interestingly, recent data suggests that the inclusion of a CTLA4 inhibitor in conjunction with a MUC1 mRNA nanovaccine enhances the therapeutic impact of the anti-CTLA-4 monoclonal antibody and adjusts the immune resistance within the tumor immune microenvironment (TME) [63].